The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...

The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.

The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.